The Evolocumab for Early Reduction of LDL‐Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) trial was the first to assess PCSK9 inhibitor antibody treatment during the acute phase of ACS.38 This evidence concerns the gene PCSK9 and acute coronary syndrome.